

# CITATION REPORT

List of articles citing

**Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling**

**DOI: 10.1161/circheartfailure.109.873240**

**Circulation: Heart Failure, 2009, 2, 684-91.**

**Source:** <https://exaly.com/paper-pdf/45519850/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #   | Paper  | IF  | Citations |
|-----|--|-----|-----------|
| 282 | Genetics of interleukin 1 receptor-like 1 in immune and inflammatory diseases. <b>2010</b> , 11, 591-606   |     | 36        |
| 281 | Protein therapeutics for cardiac regeneration after myocardial infarction. <b>2010</b> , 3, 469-77   |     | 89        |
| 280 | ST2: a novel remodeling biomarker in acute and chronic heart failure. <b>2010</b> , 7, 9-14  |     | 74        |
| 279 | Biomarkers in acute myocardial infarction. <b>2010</b> , 8, 34   |     | 142       |
| 278 | Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. <b>2010</b> , 56, 1814-21  |     | 40        |
| 277 | Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). <b>2010</b> , 285, 21478-86  |     | 53        |
| 276 | Interleukin-33, a novel member of the IL-1/IL-18 cytokine family, in cardiology and cardiac surgery. <b>2010</b> , 58, 443-9   |     | 17        |
| 275 | IL-33 and IL-33 receptors in host defense and diseases. <b>2010</b> , 59, 143-60   |     | 156       |
| 274 | ST2 and mortality in non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , <b>2010</b> , 159, 788-94   | 4.9 | 61        |
| 273 | Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. <b>2011</b> , 13, 718-25                           |     | 185       |
| 272 | Interleukin-33 biology with potential insights into human diseases. <b>2011</b> , 7, 321-9   |     | 160       |
| 271 | The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. <b>2011</b> , 179, 211-22   |     | 89        |
| 270 | The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease. <b>2011</b> , 131, 179-86   |     | 113       |
| 269 | Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. <b>2011</b> , 107, 259-67 |     | 161       |
| 268 | Soluble ST2 is a marker for acute cardiac allograft rejection. <b>2011</b> , 92, 2118-24   |     | 30        |
| 267 | Established and novel biomarkers in ST-elevation myocardial infarction. <b>2011</b> , 7, 523-46  |     |           |
| 266 | Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. <b>2011</b> , 10, 101                                       |     | 45        |

|     |  |     |     |
|-----|--|-----|-----|
| 265 | Role of IL-33 in inflammation and disease. <b>2011</b> , 8, 22   |     | 293 |
| 264 | Directions from Hecate: towards a multi-marker approach for heart failure assessment. <b>2011</b> , 13, 691-3  |     | 3   |
| 263 | Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. <b>2011</b> , 57, 874-82  |     | 68  |
| 262 | Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. <b>2011</b> , 31, 2080-9    |     | 109 |
| 261 | ST2 and IL-33 in pregnancy and pre-eclampsia. <i>PLoS ONE</i> , <b>2011</b> , 6, e24463  | 3.7 | 58  |
| 260 | IL-1 family cytokines trigger sterile inflammatory disease. <i>Frontiers in Immunology</i> , <b>2012</b> , 3, 315  | 8.4 | 112 |
| 259 | Soluble ST2 is regulated by p75 neurotrophin receptor and predicts mortality in diabetic patients with critical limb ischemia. <b>2012</b> , 32, e149-60                         |     | 33  |
| 258 | Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. <b>2012</b> , 58, 1673-81                              |     | 124 |
| 257 | Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. <b>2012</b> , 58, 257-66  |     | 115 |
| 256 | IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 366-75           | 7.6 | 38  |
| 255 | Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. <b>2012</b> , 94, 370-8                                |     | 40  |
| 254 | Cross talk between cardiac myocytes and fibroblasts: from multiscale investigative approaches to mechanisms and functional consequences. <b>2012</b> , 303, H1385-96             |     | 85  |
| 253 | Cardiokines: recent progress in elucidating the cardiac secretome. <b>2012</b> , 126, e327-32  |     | 83  |
| 252 | Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. <b>2012</b> , 126, 1596-604   |     | 334 |
| 251 | Emerging biomarkers in heart failure. <b>2012</b> , 58, 127-38   |     | 179 |
| 250 | Protective role of IL-33/ST2 axis in Con A-induced hepatitis. <b>2012</b> , 56, 26-33  |     | 113 |
| 249 | Interleukin-33 and the function of innate lymphoid cells. <b>2012</b> , 33, 389-96   |     | 106 |
| 248 | ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. <b>2012</b> , 18, 304-10 |     | 45  |

|     |   |     |
|-----|---|-----|
| 247 | Effects of interleukin-33 on cardiac fibroblast gene expression and activity. <b>2012</b> , 58, 368-79  | 34  |
| 246 | Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress. <b>2012</b> , 10, 120  | 34  |
| 245 | Novel biomarkers in chronic heart failure. <b>2012</b> , 9, 347-59  | 80  |
| 244 | Inflammation and Atherosclerosis. <b>2012</b> ,   | 3   |
| 243 | Control of inflammatory heart disease by CD4+ T cells. <b>2013</b> , 1285, 80-96  | 16  |
| 242 | New biomarkers and heart failure. <b>2013</b> , 55, e345-e354   | 4   |
| 241 | Biomarkers in organ failure. <b>2013</b> , 3, 97-104  |     |
| 240 | Association of interleukin-33 gene single nucleotide polymorphisms with ischemic stroke in north Chinese population. <b>2013</b> , 14, 109  | 19  |
| 239 | The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers. <b>2013</b> , 10, 441-9   | 22  |
| 238 | Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. <b>2013</b> , 19, 821-8   | 57  |
| 237 | Implications for Interleukin-33 in solid organ transplantation. <b>2013</b> , 62, 183-94  | 24  |
| 236 | Soluble ST2 levels are not associated with secondary cardiovascular events and vulnerable plaque phenotype in patients with carotid artery stenosis. <b>2013</b> , 231, 48-53                                 | 16  |
| 235 | Temporal changes of soluble ST2 after cardiovascular interventions. <b>2013</b> , 43, 113-20  | 17  |
| 234 | High plasma levels of soluble ST2 but not its ligand IL-33 is associated with severe forms of pediatric dengue. <b>2013</b> , 61, 766-71  | 25  |
| 233 | ST2 as a cardiovascular risk biomarker: from the bench to the bedside. <b>2013</b> , 6, 493-500   | 66  |
| 232 | Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. <b>2013</b> , 153, 828-39   | 629 |
| 231 | The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. <b>2013</b> , 13, 13-30  | 61  |
| 230 | IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxical role for inflammatory mediators?. <b>2013</b> , 2013, 498703 | 25  |

|     |  |     |    |
|-----|--|-----|----|
| 229 | Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. <b>2013</b> , 2, e000399                               |     | 58 |
| 228 | Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome. <b>2013</b> , 41, 2521-31                             |     | 38 |
| 227 | Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 1172-9                | 7.6 | 95 |
| 226 | Soluble concentrations of the interleukin receptor family member ST2 and $\beta$ -blocker therapy in chronic heart failure. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 1206-13       | 7.6 | 91 |
| 225 | Levels of interleukin 33 and soluble suppression of tumorigenicity 2 in acute ischemic stroke. <b>2013</b> , 4, 339-347  |     | 1  |
| 224 | Interleukin receptor family member ST2 concentrations in patients following heart transplantation. <i>Biomarkers</i> , <b>2013</b> , 18, 250-6   | 2.6 | 13 |
| 223 | Soluble ST2 predicts elevated SBP in the community. <b>2013</b> , 31, 1431-6; discussion 1436  |     | 35 |
| 222 | Old and newer biomarkers in heart failure: from pathophysiology to clinical significance. <b>2013</b> , 14, 690-7  |     | 8  |
| 221 | A novel cardiac bio-marker: ST2: a review. <b>2013</b> , 18, 15314-28  |     | 85 |
| 220 | Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. <i>PLoS ONE</i> , <b>2014</b> , 9, e95055                                  | 3.7 | 56 |
| 219 | Aerobic exercise training induces an anti-apoptotic milieu in myocardial tissue. <b>2014</b> , 20, 233-238   |     | 6  |
| 218 | The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects. <b>2014</b> , 28, 432-7  |     | 19 |
| 217 | Virus-like particles presenting interleukin-33 molecules: immunization characteristics and potentials of blocking IL-33/ST2 pathway in allergic airway inflammation. <b>2014</b> , 10, 2303-11 |     | 14 |
| 216 | Unique temporal and spatial expression patterns of IL-33 in ovaries during ovulation and estrous cycle are associated with ovarian tissue homeostasis. <b>2014</b> , 193, 161-9                |     | 26 |
| 215 | Emerging biomarkers in heart failure and cardiac cachexia. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 23878-96   | 6.3 | 28 |
| 214 | Associations between variants in IL-33/ST2 signaling pathway genes and coronary heart disease risk. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 23227-39            | 6.3 | 13 |
| 213 | IL-33/ST2 axis promotes mast cell survival via BCLXL. <b>2014</b> , 111, 10281-6   |     | 47 |
| 212 | Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. <b>2014</b> , 44, 643-51   |     | 45 |

|     |  |      |    |
|-----|--|------|----|
| 211 | ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality. <b>2014</b> , 100, 1715-21  |      | 28 |
| 210 | Cardiomyocyte-specific transforming growth factor $\beta$ suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction. <i>Circulation Research</i> , <b>2014</b> , 114, 1246-57 | 15.7 | 73 |
| 209 | Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. <b>2014</b> , 60, 530-40   |      | 82 |
| 208 | Interleukin-33: A Multifunctional Alarmin that Promotes Both Health and Disease. <b>2014</b> , 267-299   |      | 1  |
| 207 | Soluble ST2 and galectin-3 in heart failure. <b>2014</b> , 34, 87-97, vi-vii   |      | 25 |
| 206 | Cardiac fibroblasts protect cardiomyocytes against lethal ischemia-reperfusion injury. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2014</b> , 68, 56-65   | 5.8  | 52 |
| 205 | Cytokine Frontiers. <b>2014</b> ,  |      | 12 |
| 204 | Novel biomarkers in heart failure with preserved ejection fraction. <b>2014</b> , 10, 471-9  |      | 16 |
| 203 | Cardiac biomarkers in heart failure. <b>2014</b> , 47, 327-37  |      | 39 |
| 202 | Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. <b>2014</b> , 451, 8-14   |      | 47 |
| 201 | Biomarkers of cardiovascular stress and subclinical atherosclerosis in the community. <b>2014</b> , 60, 1402-8   |      | 15 |
| 200 | Cardiac molecular markers of programmed cell death are activated in end-stage heart failure patients supported by left ventricular assist device. <b>2014</b> , 23, 272-82   |      | 10 |
| 199 | Biomarkers for risk prediction in acute decompensated heart failure. <b>2014</b> , 11, 246-59  |      | 15 |
| 198 | Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhood pulmonary arterial hypertension. <b>2014</b> , 78, 436-42   |      | 28 |
| 197 | Serum Concentrations of Interleukin-33 and its Soluble Receptor sST2 in Patients with Persistent Atrial Fibrillation. <b>2015</b> , 06,  |      |    |
| 196 | The Protective Role of Interleukin-33 in Myocardial Ischemia and Reperfusion Is Associated with Decreased HMGB1 Expression and Up-Regulation of the P38 MAPK Signaling Pathway. <i>PLoS ONE</i> , <b>2015</b> , 10, e0143064                                       | 3.7  | 26 |
| 195 | Cellular Communications in the Heart. <b>2015</b> , 1, 64-68   |      | 25 |
| 194 | Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2. <b>2015</b> , 10, 37-41  |      | 3  |

|     |  |       |
|-----|--|-------|
| 193 | Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. <b>2015</b> , 112, 7249-54  | 102   |
| 192 | The Role of Inflammation in Myocardial Infarction. <b>2015</b> , 39-65   | 2     |
| 191 | The potential role of IL-33/ST2 signaling in fibrotic diseases. <b>2015</b> , 98, 15-22  | 35    |
| 190 | The cytokines of pulmonary fibrosis: Much learned, much more to learn. <b>2015</b> , 74, 88-100  | 58    |
| 189 | Actual position of interleukin(IL)-33 in atherosclerosis and heart failure: Great Expectations or En attendant Godot?. <b>2015</b> , 30, 356-74                  | 5     |
| 188 | The role of IL-33/ST2L signals in the immune cells. <b>2015</b> , 164, 11-7  | 48    |
| 187 | The biology of ST2: the International ST2 Consensus Panel. <b>2015</b> , 115, 3B-7B  | 152   |
| 186 | Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation. <b>2015</b> , 42, 1005-19  | 364   |
| 185 | Soluble ST2 in Ventricular Dysfunction. <b>2015</b> , 69, 139-59   | 4     |
| 184 | ST2 in Pulmonary Disease. <b>2015</b> , 115, 44B-7B  | 17    |
| 183 | ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. <b>2015</b> , 115, 70B-5B                                       | 62    |
| 182 | Soluble ST2 may possess special superiority as a risk predictor in heart failure patients. <i>International Journal of Cardiology</i> , <b>2015</b> , 186, 146-7 | 3.2 3 |
| 181 | The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atherosclerosis. <b>2015</b> , 1852, 1498-510      | 61    |
| 180 | Serial ST2 testing in hospitalized patients with acute heart failure. <b>2015</b> , 115, 32B-7B  | 26    |
| 179 | ST2 in Heart Failure: Where Does This New Marker Fit in?. <b>2015</b> , 3, 55-61   |       |
| 178 | Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. <b>2015</b> , 104, 491-9                               | 42    |
| 177 | ST2 in stable and unstable ischemic heart diseases. <b>2015</b> , 115, 48B-58B   | 28    |
| 176 | ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. <b>2015</b> , 115, 26B-31B                                      | 54    |

|     |  |      |    |
|-----|--|------|----|
| 175 | New dog and new tricks: evolving roles for IL-33 in type 2 immunity. <b>2015</b> , 97, 1037-48   |      | 59 |
| 174 | Ischemia and reperfusion related myocardial inflammation: A network of cells and mediators targeting the cardiomyocyte. <b>2015</b> , 67, 110-9  |      | 21 |
| 173 | The Current and Potential Clinical Relevance of Heart Failure Biomarkers. <b>2015</b> , 12, 318-27   |      | 9  |
| 172 | Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. <b>2015</b> , 3, 50-58 |      | 62 |
| 171 | Caspase-1 transcripts in failing human heart after mechanical unloading. <b>2015</b> , 24, 11-8  |      | 9  |
| 170 | Quantitative phosphoproteomic analysis of IL-33-mediated signaling. <b>2015</b> , 15, 532-44   |      | 42 |
| 169 | Soluble ST2 in heart failure. <i>Clinica Chimica Acta</i> , <b>2015</b> , 443, 57-70   | 6.2  | 88 |
| 168 | Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction. <b>2016</b> , 36, 313-9   |      | 15 |
| 167 | Cardiac Regeneration using Growth Factors: Advances and Challenges. <b>2016</b> , 107, 271-275   |      | 35 |
| 166 | Interleukin-33-induced immune tolerance is associated with the imbalance of memory and naïve T-lymphocyte subsets. <b>2016</b> , 14, 4837-4843   |      | 4  |
| 165 | Regenerative pharmacology: recent developments and future perspectives. <b>2016</b> , 11, 859-870  |      | 4  |
| 164 | Increased plasma VEGF levels following ischemic preconditioning are associated with downregulation of miRNA-762 and miR-3072-5p. <i>Scientific Reports</i> , <b>2016</b> , 6, 36758            | 4.9  | 25 |
| 163 | Soluble ST2, the vitamin D/PTH axis and the heart: New interactions in the air?. <i>International Journal of Cardiology</i> , <b>2016</b> , 212, 292-4   | 3.2  | 6  |
| 162 | Cardiac Fibroblast GRK2 Deletion Enhances Contractility and Remodeling Following Ischemia/Reperfusion Injury. <i>Circulation Research</i> , <b>2016</b> , 119, 1116-1127                       | 15.7 | 59 |
| 161 | Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure. <b>2016</b> , 13, 207-218   |      | 11 |
| 160 | The role of cardiac biochemical markers in aortic stenosis. <i>Biomarkers</i> , <b>2016</b> , 21, 316-27   | 2.6  | 12 |
| 159 | Elevated circulating sST2 associated with subclinical atherosclerosis in newly diagnosed primary hypertension. <b>2016</b> , 39, 513-8   |      | 12 |
| 158 | Clinical relevance of sST2 in cardiac diseases. <b>2016</b> , 54, 29-35  |      | 38 |



|     |  |        |
|-----|--|--------|
| 157 | Innate Lymphoid Cells: A Promising New Regulator in Fibrotic Diseases. <b>2016</b> , 35, 399-414   | 9      |
| 156 | IL1RL1 single nucleotide polymorphism predicts sST2 level and mortality in coronary and peripheral artery disease. <b>2017</b> , 257, 71-77  | 6      |
| 155 | A functional variant in ST2 gene is associated with risk of hypertension via interfering MiR-202-3p. <b>2017</b> , 21, 1292-1299   | 10     |
| 154 | Intercellular Signalling Cross-Talk: To Kill, To Heal and To Rejuvenate. <b>2017</b> , 26, 648-659   | 16     |
| 153 | Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. <b>2017</b> , 14, 106-116  | 12     |
| 152 | Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. <b>2017</b> , 138, 73-80  | 34     |
| 151 | Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome. <b>2017</b> , 45, e666-e673       | 19     |
| 150 | Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study. <b>2017</b> , 31, 167-177 | 14     |
| 149 | Effects of obesity on IL-33/ST2 system in heart, adipose tissue and liver: study in the experimental model of Zucker rats. <b>2017</b> , 102, 354-359  | 12     |
| 148 | Role of Vitamin D in Cardiovascular Diseases. <b>2017</b> , 46, 1039-1059  | 64     |
| 147 | Interleukin-33 attenuates doxorubicin-induced cardiomyocyte apoptosis through suppression of ASK1/JNK signaling pathway. <b>2017</b> , 493, 1288-1295  | 12     |
| 146 | Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. <b>2017</b> , 31, 2355-2365   | 3      |
| 145 | Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72'H in an Experimental Rat Model of Acute Myocardial Infarction. <b>2017</b> , 10, 460-469                          | 4      |
| 144 | Genome-wide RNA-Sequencing analysis identifies a distinct fibrosis gene signature in the conjunctiva after glaucoma surgery. <i>Scientific Reports</i> , <b>2017</b> , 7, 5644   | 4-9 11 |
| 143 | Are Inflammatory Cytokines Associated with Pain during Acute Myocardial Infarction?. <b>2017</b> , 24, 154-161   | 2      |
| 142 | Compelling Benefit of Soluble Suppression of Tumorigenicity-2 in Post-Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic. <b>2017</b> , 6,                                    | 6      |
| 141 | The integrated value of sST2 and global longitudinal strain in the early stratification of patients with severe aortic valve stenosis: a translational imaging approach. <b>2017</b> , 33, 1915-1920                     | 8      |
| 140 | Novel Biomarkers of Heart Failure. <b>2017</b> , 79, 93-152  | 60     |

|     |  |     |     |
|-----|--|-----|-----|
| 139 | Wounds that heal and wounds that don't - The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis. <b>2017</b> , 61, 41-50   |     | 26  |
| 138 | Increased Soluble ST2 Level Predicts All-Cause and Cardiovascular Mortality in Maintenance Hemodialysis Patients: A Prospective Cohort Study. <b>2017</b> , 43, 37-45                            |     | 12  |
| 137 | Comparison Between Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emergency Department With Chest Pain. <b>2017</b> , 37, 137-146 |     | 16  |
| 136 | The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 475-484   | 8.4 | 235 |
| 135 | Hepatoma-Derived Growth Factor Secreted from Mesenchymal Stem Cells Reduces Myocardial Ischemia-Reperfusion Injury. <b>2017</b> , 2017, 1096980  |     | 3   |
| 134 | IL-33-ST2 Axis in Liver Disease: Progression and Challenge. <b>2017</b> , 2017, 5314213  |     | 15  |
| 133 | Cardiokines as Modulators of Stress-Induced Cardiac Disorders. <b>2017</b> , 108, 227-256  |     | 18  |
| 132 | Prognostic role of soluble ST2 on cardiovascular mortality in outpatients with heart failure. <i>Anatolian Journal of Cardiology</i> , <b>2017</b> , 18, 200-205                                 | 0.8 | 5   |
| 131 | GDF-15 is a better complementary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2. <b>2018</b> , 22, 2422-2429                       |     | 16  |
| 130 | A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today?. <b>2018</b> , 7, 25-44   |     | 62  |
| 129 | An ST2-dependent role of bone marrow-derived group 2 innate lymphoid cells in pulmonary fibrosis. <b>2018</b> , 245, 399-409   |     | 18  |
| 128 | Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy. <b>2018</b> , 130, 299-307                 |     | 13  |
| 127 | Eplerenone Modulates Interleukin-33/sST2 Signaling and IL-1 $\beta$ in Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. <b>2018</b> , 38, 137-144                        |     | 13  |
| 126 | Association of soluble ST2 with functional capacity in outpatients with heart failure. <b>2018</b> , 43, 455-460   |     | 8   |
| 125 | Soluble ST2 in Heart Failure. <b>2018</b> , 14, 41-48  |     | 49  |
| 124 | Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction. <b>2018</b> , 131, 1282-1288                |     | 9   |
| 123 | Heart Failure Monitoring. <b>2018</b> , 453-463  |     |     |
| 122 | OBSOLETE: Heart Failure Monitoring. <b>2018</b> ,  |     |     |

|     |  |     |    |
|-----|--|-----|----|
| 121 | ST2 elevation in heart failure, predictive of a high early mortality. <b>2018</b> , 70, 822-827  |     | 6  |
| 120 | IL-33/ST2 Axis in Organ Fibrosis. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2432   | 8.4 | 78 |
| 119 | Cardioprotective cytokine interleukin-33 is up-regulated by statins in human cardiac tissue. <b>2018</b> , 22, 6122-6133   |     | 7  |
| 118 | The Impact of Invariant NKT Cells in Sterile Inflammation: The Possible Contribution of the Alarmin/Cytokine IL-33. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2308 | 8.4 | 12 |
| 117 | Conflicting vascular and metabolic impact of the IL-33/sST2 axis. <b>2018</b> , 114, 1578-1594   |     | 53 |
| 116 | IL-33 receptor (ST2) deficiency downregulates myeloid precursors, inflammatory NK and dendritic cells in early phase of sepsis. <b>2018</b> , 25, 56                       |     | 10 |
| 115 | Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. <b>2018</b> , 14, 890-909                               |     | 34 |
| 114 | Elevated ST2 levels are associated with antibody-mediated rejection in heart transplant recipients. <b>2018</b> , 32, e13349   |     | 6  |
| 113 | Inflammasome, T Lymphocytes and Innate-Adaptive Immunity Crosstalk: Role in Cardiovascular Disease and Therapeutic Perspectives. <b>2018</b> , 118, 1352-1369              |     | 8  |
| 112 | The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers. <b>2018</b> , 15, 239-249  |     | 12 |
| 111 | Predictive value of soluble ST2 in adolescent and adult patients with complex congenital heart disease. <i>PLoS ONE</i> , <b>2018</b> , 13, e0202406                       | 3.7 | 8  |
| 110 | Therapeutic Strategies for Targeting IL-33/ST2 Signalling for the Treatment of Inflammatory Diseases. <b>2018</b> , 49, 349-358  |     | 33 |
| 109 | GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. <b>2018</b> , 72, 519-528   |     | 54 |
| 108 | Prognostic values of novel biomarkers in patients with AL amyloidosis. <i>Scientific Reports</i> , <b>2019</b> , 9, 12200  | 4.9 | 2  |
| 107 | Alteration of the IL-33-sST2 pathway in hypertensive patients and a mouse model. <b>2019</b> , 42, 1664-1671   |     | 3  |
| 106 | LncRNA ANRIL knockdown relieves myocardial cell apoptosis in acute myocardial infarction by regulating IL-33/ST2. <b>2019</b> , 18, 3393-3403                              |     | 21 |
| 105 | Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. <b>2019</b> , 74, 2193-2203  |     | 49 |
| 104 | Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study. <b>2019</b> , 8, e012336             |     | 23 |

|     |   |     |    |
|-----|---|-----|----|
| 103 | Vitamin D Attenuates Oxidative Damage and Inflammation in Retinal Pigment Epithelial Cells. <b>2019</b> , 8,  |     | 25 |
| 102 | Periodontitis is associated with elevated serum levels of cardiac biomarkers-Soluble ST2 and C-reactive protein. <b>2019</b> , 46, 809-818                                      |     | 11 |
| 101 | ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans. <i>Clinica Chimica Acta</i> , <b>2019</b> , 495, 493-500                 | 6.2 | 24 |
| 100 | Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction. <b>2019</b> , 24, 100370                                      |     | 19 |
| 99  | Mast Cells in Cardiac Fibrosis: New Insights Suggest Opportunities for Intervention. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 580                                     | 8.4 | 31 |
| 98  | IL33 attenuates ventricular remodeling after myocardial infarction through inducing alternatively activated macrophages ethical standards statement. <b>2019</b> , 854, 307-319 |     | 6  |
| 97  | The role of the IL-33/ST2 axis in autoimmune disorders: Friend or foe?. <b>2019</b> , 50, 60-74   |     | 19 |
| 96  | Interleukin-33 Promotes REG3 $\beta$ Expression in Intestinal Epithelial Cells and Regulates Gut Microbiota. <b>2019</b> , 8, 21-36   |     | 13 |
| 95  | Regulation of Type 2 Immunity in Myocardial Infarction. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 62   | 8.4 | 19 |
| 94  | Evolving Use of Biomarkers in the Management of Heart Failure. <b>2019</b> , 27, 153-159  |     | 12 |
| 93  | Biomarkers to Assess and Guide the Management of Heart Failure. <b>2019</b> , 97-108  |     |    |
| 92  | Using Peptidomics to Identify Extracellular Matrix-Derived Peptides as Novel Therapeutics for Cardiac Disease. <b>2019</b> , 349-365  |     |    |
| 91  | Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI. <b>2019</b> , 60, 19-26                      |     | 12 |
| 90  | IL (Interleukin)-33 Suppresses Abdominal Aortic Aneurysm by Enhancing Regulatory T-Cell Expansion and Activity. <b>2019</b> , 39, 446-458                                       |     | 22 |
| 89  | Different ST2 Serum Concentrations in Asymptomatic and Symptomatic Carotid Artery Stenosis. <b>2019</b> , 56, 240-245   |     |    |
| 88  | Evaluation of serum sST2 and sCD40L values in patients with microvascular angina. <b>2019</b> , 122, 85-93  |     | 6  |
| 87  | Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects. <b>2019</b> , 56, 273-280                                 |     | 11 |
| 86  | MiR-128/SOX7 alleviates myocardial ischemia injury by regulating IL-33/sST2 in acute myocardial infarction. <b>2019</b> , 400, 533-544  |     | 12 |

|    |   |      |    |
|----|---|------|----|
| 85 | Cardioprotective effect of the secretome of Sca-1+ and Sca-1- cells in heart failure: not equal, but equally important?. <b>2020</b> , 116, 566-575   |      | 6  |
| 84 | Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST-2, in thoracic cancer chest radiation. <b>2020</b> , 34, e23150  |      | 4  |
| 83 | Reappraisal of Inflammatory Biomarkers in Heart Failure. <b>2020</b> , 17, 9-19   |      | 9  |
| 82 | Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. <i>American Heart Journal</i> , <b>2020</b> , 220, 253-263   | 4.9  | 4  |
| 81 | Pathophysiology and molecular signalling in pediatric heart failure and VAD therapy. <i>Clinica Chimica Acta</i> , <b>2020</b> , 510, 751-759   | 6.2  | 2  |
| 80 | Innate Immunity Effector Cells as Inflammatory Drivers of Cardiac Fibrosis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,  | 6.3  | 10 |
| 79 | Mortality in cardiogenic shock is stronger associated to clinical factors than contemporary biomarkers reflecting neurohormonal stress and inflammatory activation. <i>Biomarkers</i> , <b>2020</b> , 25, 506-512 <sup>2.6</sup>                                |      | 0  |
| 78 | Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 595053   | 8.4  | 3  |
| 77 | Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction. <i>Scientific Reports</i> , <b>2020</b> , 10, 18663  | 4.9  | 3  |
| 76 | Cardiac Biomarkers and Risk of Mortality in CKD (the CRIC Study). <i>Kidney International Reports</i> , <b>2020</b> , 5, 2002-2012  | 4.1  | 7  |
| 75 | Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers. <i>Disease Markers</i> , <b>2020</b> , 2020, 1215802   | 3.2  | 21 |
| 74 | Exogenous IL-4 shuts off pro-inflammation in neutrophils while stimulating anti-inflammation in macrophages to induce neutrophil phagocytosis following myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2020</b> , 145, 112-121 | 5.8  | 12 |
| 73 | Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure. <i>Clinical Pharmacology: Advances and Applications</i> , <b>2020</b> , 12, 53-58  | 1.5  | 4  |
| 72 | Prognostic value of soluble ST2 and soluble LR11 on mortality and cardiovascular events in peritoneal dialysis patients. <i>BMC Nephrology</i> , <b>2020</b> , 21, 228  | 2.7  | 2  |
| 71 | Proregenerative Activity of IL-33 in Gastric Tissue Cells Undergoing -Induced Apoptosis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,   | 6.3  | 3  |
| 70 | Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2. <i>Hormone Molecular Biology and Clinical Investigation</i> , <b>2020</b> , 41,  | 1.3  | 2  |
| 69 | Innate Lymphoid Cells Play a Pathogenic Role in Pericarditis. <i>Cell Reports</i> , <b>2020</b> , 30, 2989-3003.e6  | 10.6 | 16 |
| 68 | Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation. <i>Mucosal Immunology</i> , <b>2020</b> , 13, 626-636   | 9.2  | 26 |

|    |   |      |     |
|----|---|------|-----|
| 67 | The Biomarkers for Acute Myocardial Infarction and Heart Failure. <i>BioMed Research International</i> , <b>2020</b> , 2020, 2018035  | 3    | 27  |
| 66 | Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , <b>2020</b> , 304, 95-100   | 3.2  | 15  |
| 65 | Mending a broken heart: current strategies and limitations of cell-based therapy. <i>Stem Cell Research and Therapy</i> , <b>2020</b> , 11, 138   | 8.3  | 21  |
| 64 | Soluble ST2: A complex and diverse role in several diseases. <i>Clinica Chimica Acta</i> , <b>2020</b> , 507, 75-87   | 6.2  | 27  |
| 63 | Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. <i>Circulation Research</i> , <b>2020</b> , 126, 1260-1280   | 15.7 | 165 |
| 62 | The Role of IL-33 in Experimental Heart Transplantation. <i>Cardiology Research and Practice</i> , <b>2020</b> , 2020, 6108362  | 1.9  | 1   |
| 61 | The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. <i>Heart Failure Reviews</i> , <b>2021</b> , 26, 799-812 | 5    | 10  |
| 60 | Sterile inflammation in thoracic transplantation. <i>Cellular and Molecular Life Sciences</i> , <b>2021</b> , 78, 581-601   | 10.3 | 10  |
| 59 | Group 2 innate lymphoid cells contribute to IL-33-mediated alleviation of cardiac fibrosis. <i>Theranostics</i> , <b>2021</b> , 11, 2594-2611   | 12.1 | 6   |
| 58 | Gender-Related Differences in Heart Failure Biomarkers. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 617705   | 5.4  | 5   |
| 57 | The effect of chronic intermittent hypoxia in cardiovascular gene expression is modulated by age in a mice model of sleep apnea. <i>Sleep</i> , <b>2021</b> , 44,   | 1.1  | 1   |
| 56 | Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,  | 6.3  | 1   |
| 55 | Soluble ST2 levels for predicting the presence and severity of metabolic syndrome. <i>Endocrine Connections</i> , <b>2021</b> , 10, 336-344   | 3.5  | 2   |
| 54 | Novel biomarkers in cardiovascular surgery. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 307-318   | 2.3  | 1   |
| 53 | X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc). <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,  | 2.4  | 0   |
| 52 | Lack of prognostic significance for major adverse cardiac events of soluble suppression of tumorigenicity 2 levels in patients with ST-segment elevation myocardial infarction. <i>Cardiology Journal</i> , <b>2021</b> , 28, 244-254   | 1.4  | 2   |
| 51 | A possible role for ST2 as prognostic biomarker for COVID-19. <i>Vascular Pharmacology</i> , <b>2021</b> , 138, 106857  | 5.9  | 8   |
| 50 | Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 697837   | 5.4  | 6   |

|    |   |      |    |
|----|---|------|----|
| 49 | Helium Conditioning Increases Cardiac Fibroblast Migration Which Effect Is Not Propagated via Soluble Factors or Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,   | 6.3  | 1  |
| 48 | Role of IL-33 receptor (ST2) deletion in diaphragm contractile and mitochondrial function in the Sugen5416/hypoxia model of pulmonary hypertension. <i>Respiratory Physiology and Neurobiology</i> , <b>2022</b> , 295, 103783  | 2.8  | 0  |
| 47 | IL-33 induces type-2-cytokine phenotype but exacerbates cardiac remodeling post-myocardial infarction with eosinophil recruitment, worsened systolic dysfunction, and ventricular wall rupture. <i>Clinical Science</i> , <b>2020</b> , 134, 1191-1218  | 6.5  | 5  |
| 46 | IL-33 modulates inflammatory brain injury but exacerbates systemic immunosuppression following ischemic stroke. <i>JCI Insight</i> , <b>2018</b> , 3,   | 9.9  | 23 |
| 45 | Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 5397-5412  | 15.9 | 10 |
| 44 | Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 4208-18   | 15.9 | 87 |
| 43 | IL-33 attenuates anoxia/reoxygenation-induced cardiomyocyte apoptosis by inhibition of PKC/JNK pathway. <i>PLoS ONE</i> , <b>2013</b> , 8, e56089   | 3.7  | 18 |
| 42 | Role of interleukins in heart failure with reduced ejection fraction. <i>Anatolian Journal of Cardiology</i> , <b>2019</b> , 22, 287-299  | 0.8  | 15 |
| 41 | Interleukin-1 in cardiac injury, repair, and remodeling: pathophysiologic and translational concepts. <i>Discoveries</i> , <b>2015</b> , 3,   | 3.7  | 50 |
| 40 | Predictors of myocardial fibrosis and loss of epicardial adipose tissue volume in the long-term period after myocardial infarction. <i>Russian Journal of Cardiology</i> , <b>2020</b> , 25, 31-40  | 1.3  | 4  |
| 39 | [Soluble ST2 - as a biomarker, a tool for risk stratification and therapeutic target in patients with chronic heart failure]. <i>Kardiologiya</i> , <b>2019</b> , 60, 111-121   | 1.5  | 4  |
| 38 | Biomarkers ST2 and interleukin 33 for assessing the severity of cardiac inflammation and fibrosis in patients with chronic heart failure. <i>Russian Journal of Cardiology</i> , <b>2021</b> , 26, 4530   | 1.3  | 1  |
| 37 | Prognosis value of serum soluble ST2 level in acute ischemic stroke and STEMI patients in the era of mechanical reperfusion therapy. <i>Journal of Neurology</i> , <b>2021</b> , 1  | 5.5  |    |
| 36 | Interleukin-33 and Atherosclerosis. <b>2012</b> , 239-248   |      |    |
| 35 | ST2 IN REJECTION OF THE TRANSPLANTED HEART. <i>Vestnik Transplantologii I Iskusstvennykh Organov</i> , <b>2016</b> , 17, 90-94  | 0.3  |    |
| 34 | Interleukin-33 Prevents Retinal Ischemia Reperfusion Injury in Rats by Preventing Apoptosis. <i>Iranian Red Crescent Medical Journal</i> , <b>2016</b> , 19,  | 1.3  |    |
| 33 | Prognosis of cardiovascular events after implantation of a cardioverterdefibrillator in patients with chronic heart failure: the value of increasing concentration of endothelin-1 and soluble forms of ST2 protein in blood plasma. <i>Bulletin of Siberian Medicine</i> , <b>2018</b> , 17, 140-150 | 0.4  | 2  |
| 32 | Clinical and prognostic role of the plasma level of stimulating growth factor in patients with miscellaneous cardiovascular pathology. <i>Acta Medica Leopoliensia</i> , <b>2019</b> , 25, 82-88  | 0    | 1  |

|    |   |     |    |
|----|---|-----|----|
| 31 | The concentration of interleukin-33 in heart failure with reduced ejection fraction. <i>Anatolian Journal of Cardiology</i> , <b>2019</b> , 21, 305-313   | 0.8 | 6  |
| 30 | The ST2 diagnostic value in selection of patients for heart transplantation and post-transplant period. <i>Modern Medical Technologies</i> , <b>2019</b> , 40, 4-11   | 0   |    |
| 29 | [Soluble ST2 - biomarker for prognosis and monitoring in decompensated heart failure]. <i>Kardiologiya</i> , <b>2019</b> , 59, 18-27  | 1.5 | 1  |
| 28 | Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality. <i>Experimental and Clinical Cardiology</i> , <b>2012</b> , 17, 205-9   |     | 15 |
| 27 | Innate Lymphoid Cells and Myocardial Infarction. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 758272  | 8.4 | 0  |
| 26 | Role of Inflammation and Redox Status on Doxorubicin-Induced Cardiotoxicity in Infant and Adult CD-1 Male Mice. <i>Biomolecules</i> , <b>2021</b> , 11,   | 5.9 | 0  |
| 25 | Soluble ST2 Receptor: Biomarker of Left Ventricular Impairment and Functional Status in Patients with Inflammatory Cardiomyopathy.. <i>Cells</i> , <b>2022</b> , 11,  | 7.9 | 0  |
| 24 | Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.. <i>Cells</i> , <b>2022</b> , 11,   | 7.9 | 0  |
| 23 | Protective effect of nicorandil against myocardial ischemia/reperfusion injury mediated via IL33/ST2 signaling pathway.. <i>Molecular and Cellular Biochemistry</i> , <b>2022</b> , 1   | 4.2 | 1  |
| 22 | RNA-Binding Profiles of CKAP4 as an RNA-Binding Protein in Myocardial Tissues.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 773573   | 5.4 | 0  |
| 21 | Synergistic Effects of Weighted Genetic Risk Scores and Resistin and sST2 Levels on the Prognostication of Long-Term Outcomes in Patients with Coronary Artery Disease.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, | 6.3 |    |
| 20 | Presentation_1.pptx. <b>2020</b> ,  |     |    |
| 19 | Evaluating the adverse outcome of subtypes of heart failure with preserved ejection fraction defined by machine learning: A systematic review focused on defining high risk phenogroups.. <i>EXCLI Journal</i> , <b>2022</b> , 21, 487-518      | 2.4 | 0  |
| 18 | Soluble suppression of tumorigenesis-2 (sST2) is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in hemodialysis patients with diabetes mellitus. <i>CKJ: Clinical Kidney Journal</i> ,                    | 4.5 | 0  |
| 17 | Interrelationship and Sequencing of Interleukins4, 13, 31, and 33 [An Integrated Systematic Review: Dermatological and Multidisciplinary Perspectives. Volume 15, 5163-5184   |     | 2  |
| 16 | The Role of Interleukin-33 in Organ Fibrosis.   |     | 0  |
| 15 | The correlation between maternal serum sST2, IL-33 and NT-proBNP concentrations and occurrence of pre-eclampsia in twin pregnancies: A longitudinal study.  |     | 0  |
| 14 | Serum Biomarkers for the Detection of Cardiac Dysfunction in Childhood Cancers Receiving Anthracycline-Based Treatment. <b>2022</b> , 15, 1311-1321   |     | 0  |



|    |   |   |
|----|---|---|
| 13 | Interleukin-1 in Coronary Artery Disease. <b>2022</b> , 23,   | 4 |
| 12 | Dual Immune Regulatory Roles of Interleukin-33 in Pathological Conditions. <b>2022</b> , 11, 3237   | 1 |
| 11 | IL-33/ST2 immunobiology in coronary artery disease: A systematic review and meta-analysis. 9,   | 0 |
| 10 | Growth stimulation expressed gene 2 (ST2): Clinical research and application in the cardiovascular related diseases. 9,                               | 0 |
| 9  | Advances in congestive heart failure biomarkers. <b>2022</b> ,  | 0 |
| 8  | A fluorescent nano vector for early diagnosis and enhanced Interleukin-33 therapy of thoracic aortic dissection. <b>2023</b> , 293, 121958            | 0 |
| 7  | Interleukin-33 Mediates Cardiomyopathy After Acute Kidney Injury by Signaling to Cardiomyocytes.  | 0 |
| 6  | Unveiling IL-33/ST2 Pathway Unbalance in Cardiac Remodeling Due to Obesity in Zucker Fatty Rats. <b>2023</b> , 24, 1991                               | 0 |
| 5  | GDF-15 and soluble ST2 as biomarkers of right ventricular dysfunction in pulmonary hypertension. <b>2022</b> , 16, 1193-1207                          | 0 |
| 4  | ST2 circulante: un patógeno, más que un biomarcador. <b>2023</b> ,  | 0 |
| 3  | A biomarker for bacteremia in pregnant women with acute pyelonephritis: soluble suppressor of tumorigenicity 2 or sST2. <b>2023</b> , 36,             | 0 |
| 2  | IL-33 promotes double negative T cell survival via the NF- $\kappa$ B pathway. <b>2023</b> , 14,  | 0 |
| 1  | Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE). <b>2023</b> , 12, 2790 | 0 |